The liver is the most common site of metastatic disease in colorectal cancer (CRC) due to hematogenous spread via the portal circulation. Of newly diagnosed patients, approximately a quarter of the patients will present with distant metastases, with the liver being involved in approximately 70% of all mCRC cases. As metastatic disease can occur early in the disease course and is one of the major causes of cancer-related morbidity and mortality, advances in the treatment of liver metastases are vital to controlling disease and improving survival. This chapter will discuss the epidemiologic factors and genomic mutations that predispose certain populations to hepatic mCRC, as well as the standard of care in clinical and diagnostic imaging work-up required for these patients. Finally, this chapter will explore the multidisciplinary application of multiple surgical, systemic and locoregional therapies in order to prolong survival in patients with hepatic mCRC.